8-K: Akari Therapeutics Appoints Kameel Farag as Interim CFO

Akari Therapeutics, Plc announced the appointment of Kameel Farag as its interim Chief Financial Officer, effective October 22, 2025, succeeding Torsten Hombeck.

Summary

• Akari Therapeutics, Plc appointed Kameel Farag as interim Chief Financial Officer, effective October 22, 2025.
• Mr. Farag succeeds Torsten Hombeck, whose departure was previously reported.
• Mr. Farag, 47, is a biotech and global finance executive with extensive experience, including securing over $150 million in financing and preparing a company for a potential public offering at Aspen Neuroscience, Inc.
• His compensation includes a monthly cash fee of $18,000 plus $12,000 in RSUs for October-December 2025.
• From January 1, 2026, to February 15, 2026, the monthly fee increases to $27,000 in cash plus $13,000 in RSUs.
• KDF Ventures LLC, Mr. Farag's entity, will also receive compensation for certain capital raises, ranging from 0.5% to 1.0% of gross proceeds, capped at $100,000 or $200,000 depending on the timing and amount of the raise.
• The consulting agreement is effective from October 20, 2025, with an initial term end date of February 16, 2026, extendable month-to-month at the company's discretion.

Sentiment

Score: 6

Explanation: The appointment of an experienced interim CFO is a positive step for operational continuity, but the interim nature and the capital raise compensation structure introduce some uncertainty and potential dilution concerns, balancing the overall sentiment to moderately positive.

Positives

• The company appointed an experienced biotech and global finance executive, Kameel Farag, as interim CFO, ensuring continuity in financial leadership.
• Mr. Farag's background includes successfully securing over $150 million in financing and preparing a company for clinical data and a potential future public offering, which could benefit Akari Therapeutics.
• The appointment addresses the vacancy left by the previous CFO's departure, maintaining essential financial oversight.

Negatives

• The CFO appointment is on an interim basis, indicating that a permanent replacement is still being sought, which introduces an element of uncertainty.
• The compensation structure includes significant RSU components and success fees for capital raises, which could lead to dilution for existing shareholders.
• The initial term of the consulting agreement is relatively short (until February 16, 2026), potentially leading to further management changes in the near future.

Risks

• Reliance on an interim CFO through a consulting agreement rather than a permanent employee may present challenges in long-term strategic planning and integration.
• Potential for shareholder dilution if capital raises are executed and RSU compensation is significant, impacting per-share value.
• The short initial term of the consulting agreement introduces uncertainty regarding the stability of financial leadership beyond February 2026.
• The company faces the ongoing challenge of attracting and retaining a qualified permanent Chief Financial Officer.

Future Outlook

The company anticipates potential capital raises, for which the interim CFO's consulting entity will receive success-based compensation. The interim CFO role is set to continue until at least February 16, 2026, with options for month-to-month extensions, indicating an ongoing search for a permanent solution or a flexible arrangement to manage financial operations.

Management Comments

• Mr. Farag will serve as interim Chief Financial Officer until the qualification and appointment of his successor.
• The Company agrees to notify Consultant in writing on or before January 1, 2026, if the Company decides to extend the term of this Agreement another 30 days past February 16, 2026. Thereafter, the Company may, upon written notice to the Consultant, extend the term on a month-to-month basis at the discretion of the Company.

Industry Context

In the biotech industry, securing experienced financial leadership is crucial, especially for companies undergoing transformational growth or preparing for clinical data and potential public offerings, as Mr. Farag's background suggests. Interim appointments are common to ensure continuity during transitions, but the long-term stability of financial leadership remains a key consideration for investors. The mention of capital raises is also typical for biotech firms, which often require significant funding for R&D and clinical trials.

Comparison to Industry Standards

• The appointment of an interim CFO with a strong background in biotech finance (e.g., Amgen, Ionis) is a standard practice for companies seeking to maintain financial oversight during a transition, comparable to similar moves by other small to mid-cap biotech firms.
• The compensation structure, including a base fee and performance-based incentives tied to capital raises, is a common model for engaging high-level consultants in the biotech sector, where successful fundraising is critical for growth and development.
• The explicit mention of compliance with the company's Insider Trading Policy and Executive Officer Clawback Policy aligns with best practices in corporate governance for publicly traded companies, similar to policies at Biovie Inc. (NASDAQ: BIVI) where Mr. Farag serves as a director.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution from RSU compensation and future capital raises; benefit from experienced financial leadership during a transition.
• Employees: Continuity in the CFO role provides stability; Mr. Farag's experience in scaling companies could influence future operational strategies and headcount.
• Management: The CEO and Audit Committee Chairman will work directly with the interim CFO, benefiting from his expertise in financial reporting and strategy.
• Creditors/Investors: The appointment of an experienced CFO may instill confidence in the company's financial management and reporting capabilities.

Next Steps

• The company will continue the search for a permanent Chief Financial Officer.
• Potential capital raises are anticipated, which would trigger specific compensation for the interim CFO's consulting entity.
• The company may extend the interim CFO's consulting agreement beyond February 16, 2026, on a month-to-month basis.

Key Dates

Recommendation

The appointment of an experienced interim CFO is a necessary and positive step for operational continuity, especially given the previous CFO's departure. However, the interim nature of the role and the explicit mention of future capital raises, which could lead to dilution, suggest a 'hold' recommendation. Investors should monitor the search for a permanent CFO and details of any upcoming capital raises for further clarity on the company's long-term financial strategy and stability.

Keywords

Akari Therapeutics, CFO, Interim Chief Financial Officer, Kameel Farag, Management Change, SEC Filing, 8-K, Biotech, Financial Executive, Capital Raise